Year Founded
2020
Ownership
Private
Employees
~50
Stage
Commercial
Modalities
Molecular diagnosticsNext-generation sequencing (NGS)

Inocras General Information

Provides whole genome sequencing services with AI-driven analysis for cancer and rare disease diagnostics. Offers CancerVision for tumor profiling, MRDVision for minimal residual disease detection, and RareVision for rare disease diagnosis.

Contact Information

Website
Primary Industry
Diagnostic
Corporate Office

Drug Pipeline

CancerVision
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Inocras's pipeline data

Book a demo

Key Partnerships

Summit Pharmaceuticals International Corporation, Fore Genomics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Inocras Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Inocras's complete valuation and funding history, request access »

Inocras Investors

Asan Foundation
Investor Type: Venture Capital
Holding: Minority
Samsung Ventures
Investor Type: Venture Capital
Holding: Minority
Ignite Innovation
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »